GMP Factory Supply Chemical/Pharmaceutical CAS 1197953-54-0 Brigatinib

• Powder: Yes
• Customized: Customized
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: White Powder
• Purity: >99%
• Model NO.: Frazer-Brigatinib
• Appearance: White Powder
• CAS No: 1197953-54-0
• Shelf Life: 2 Years
• Test Method: HPLC
• MOQ: 1kg
• Storage: Store Cool Dry Place
• Resource: Natural
• Quality Requirement: Strictly Quality Control
• Market: Worldwide
• Service: Welcome to Visit Us
• Mf: C29h39cln7o2p
• Grade Standard: Medicine Grade
• Transport Package: Foil Bag
• Specification: 99%
• Trademark: Xi′an Frazer Biotech Co., Ltd.
• Origin: China
• Production Capacity: 2000kg/Month

Product Description

GMP Factory Supply Chemical/Pharmaceutical CAS 1197953-54-0 Brigatinib

 

Specification of Analysis

Item	Specification
Specific rotation	+39.5 to +41.5°
State of solution(transmittance)	Clear 98.0% min.
Chloride[cl]	0.020% max.
Ammonium [NH4]	0.02% max.
Sulfate[SO4]	0.020% max
Iron[Fe]	10ppm max.
Heavy metals [Pb]	10ppm max
Arsenic[As2O3]	1ppm max
Other amino acids	Chromatographically not detectable
Loss on drying	0.20% max.
Residue on ignition[sulfated]	0.10% max.
Assay	99.0% min

Brigatinib (AP26113) is a medicine used to treat cancer that suppresses epidermal grow'th factor receptor (EGFR) and anaplastic lymphoma kinase (ALK). Brigatinib is a selective agonist against variations of EGFR as opposed to the wild mutant forms. The drug also illustrates selectivity against the ALK-EML4 fusion gene, which is a fundamental aspect of the modification of susceptible lung parenchyma. Brigatinib is prescribed for patients with specific abnormal genes and when the non-small cell lung cancer (NSCLC) is non-responsive to management with other medications. Brigatinib is classified as a kinase inhibitor, whose mechanism of action entails suppressing the action of abnormal proteins that enhance the multiplication of cancer cells.

Function & Application

Brigatinib, also known as AP-26113, is an orally active, potent and selective Dual ALK/EGFR inhibitor. AP26113 binds to and inhibits ALK kinase and ALK fusion proteins as well as EGFR and mutant forms. This leads to the inhibition of ALK kinase and EGFR kinase, disrupts their signaling pathways and eventually inhibits tumor cell growth in susceptible tumor cells. In addition, AP26113 appears to overcome mutation-based resistance. ALK belongs to the in'sulin receptor superfamily and plays an important role in nervous system development; ALK dysregulation and gene rearrangements are associated with a series of tumors. EGFR is overexpressed in a variety of cancer cell types.